The global sublingual allergy immunotherapy market size is expected to be valued at US$ 1.1 billion in 2026 and projected to reach US$ 2 billion, growing at a CAGR of 9.2% between 2026 and 2033. This trajectory is underpinned by the rise in global prevalence of allergic diseases now affecting more than 30% of the world's population, according to the World Allergy Organization (WAO), and the decisive patient and physician preference shift toward sublingual immunotherapy (SLIT) as a disease-modifying, non-invasive alternative to subcutaneous injection.

FDA approvals of standardized SLIT tablets including Odactra (ALK-Abelló / Merck), Grastek, Ragwitek, and Oralair (Stallergenes Greer) have legitimized the category in the commercially critical North American market, while expanding reimbursement frameworks in Europe and growing regulatory activity in Asia-Pacific are accelerating global prescription uptake throughout the forecast period.

Drivers - Surging Global Allergic Disease Burden Driving Immunotherapy Adoption Beyond Symptomatic Management

The global rise in burden of allergic rhinitis, allergic asthma, and atopic conditions is a structural market driver transforming patient and prescriber interest from symptomatic pharmacotherapy toward disease-modifying sublingual immunotherapy. The World Allergy Organization (WAO) estimates that allergic diseases affect over 30–40% of the global population, with prevalence continuing to rise due to urbanization, pollution, and the hygiene hypothesis.

The European Academy of Allergy and Clinical Immunology (EAACI) projects that over 50% of the EU population will be affected by some form of allergy by 2025. Unlike antihistamines and corticosteroids, which provide only temporary symptom relief, sublingual immunotherapy addresses the underlying immune dysregulation, offering long-term remission in 60–80% of patients according to clinical data summarized in the Journal of Allergy and Clinical Immunology, creating compelling therapeutic differentiation that is accelerating prescriber adoption and patient demand.

Restraints - Long Treatment Duration and Patient Compliance Challenges Limiting Sustained Market Penetration

Sublingual immunotherapy requires 3 to 5 years of consistent daily self-administration to achieve sustained clinical benefit a treatment duration that presents significant patient adherence challenges. Published studies in Allergy journal document that real-world SLIT adherence rates drop to approximately 50–60% by year two of treatment, substantially below the compliance levels achieved in controlled clinical trials. Treatment discontinuation before the completion of the full immunotherapy course reduces clinical effectiveness and may limit the long-term economic justification versus symptomatic pharmacotherapy, dampening physician confidence in SLIT outcomes and creating a ceiling on market conversion rates from conventional allergy treatment pathways.

Opportunities - Odactra (House Dust Mite SLIT): Fastest-Growing Drug Segment with Large Unmet Need

Odactra (house dust mite sublingual tablet), jointly developed by ALK-Abelló and commercialized in partnership with Merck in the United States, represents the fastest-growing drug segment in the sublingual allergy immunotherapy market. House dust mite (HDM) allergy is the most prevalent indoor allergen sensitization globally, with the WAO estimating that HDM sensitization affects over one billion individuals worldwide and is a leading trigger of perennial allergic rhinitis and allergic asthma.

Unlike grass and weed pollen SLIT products whose use is seasonal, Odactra prescribing is year-round due to the perennial nature of HDM exposure, generating more consistent prescription volumes and superior revenue per patient versus seasonal SLIT products. The global expansion of Odactra and comparable HDM SLIT products by ALK-Abelló across European and Asia-Pacific markets represents a significant revenue growth catalyst through the 2033 forecast horizon.

Drug Insights

Oralair (five-grass pollen sublingual tablet, marketed by Stallergenes Greer) accounts for the leading position in the drug segment of the sublingual allergy immunotherapy market, commanding approximately 25% of global revenue share in 2026. Oralair’s leadership is anchored by its broad 5-grass pollen formulation coverage encompassing orchard, sweet vernal, perennial rye, timothy, and Kentucky blue grasses which provides superior population-level allergen coverage versus single-grass SLIT products in geographically diverse markets.

Oralair is approved by EMA and has reimbursement facilities in multiple European national health insurance systems in Germany, France, Spain, and other high-prevalence European grass pollen allergy markets. Its established physician prescribing familiarity and patient education infrastructure across Europe and growing U.S. post-approval penetration sustain its segment leadership throughout the near-to-medium term forecast.

Allergen Insights

Pollen (comprising grass, weed, and tree pollen sub-categories) constitutes the leading allergen segment in the sublingual allergy immunotherapy market, accounting for approximately 52% of global revenues in 2026. Pollen allergy is the most prevalent outdoor allergen sensitization globally, with the EAACI documenting that seasonal allergic rhinitis caused by pollen affects approximately 20–30% of adults and up to 40% of children in Europe alone.

The availability of multiple EMA and FDA-approved standardized grass pollen SLIT tablet products (Grastek, Oralair, Actair) has established robust prescribing infrastructure and insurance reimbursement pathways for pollen immunotherapy in key markets, driving sustained high-volume prescription generation particularly during pre-seasonal treatment initiation windows that characterize pollen SLIT clinical protocols.

North America Sublingual Allergy Immunotherapy Market Trends and Insights

North America continues to dominate the sublingual allergy immunotherapy (SLIT) market, driven by high allergic disease prevalence, advanced clinical adoption, and strong healthcare infrastructure. The regional market is expected to reach ~US$ 360 Mn by 2026, supported by increasing recognition of allergen immunotherapy as a disease-modifying approach rather than symptomatic treatment. Growth is further strengthened by strong presence of FDA-approved SLIT tablets, high specialist density, and increasing patient preference for home-based treatment options.

U.S. Sublingual Allergy Immunotherapy Market Trends and Insights

The U.S. leads the region due to over 50 million individuals affected by allergic rhinitis annually (CDC estimates), along with rising comorbidity with asthma. Strong penetration of ALK Abelló SLIT products, robust allergy testing infrastructure, and increasing adoption of guideline-based immunotherapy support demand. Additional growth drivers include strong insurance coverage for allergy diagnostics, rising pediatric allergy burden, increasing environmental allergen exposure, and growing use of telehealth platforms for allergy consultations. Expansion of academic allergy research centers is also accelerating clinical uptake.

Canada Sublingual Allergy Immunotherapy Market Trends and Insights

Canada is witnessing steady growth due to increasing seasonal pollen allergies linked to climate change and longer allergy seasons. Rising awareness of immunotherapy and expanding allergy specialty clinics in urban centers are improving diagnosis rates. Additional drivers include government-supported healthcare access, increasing pediatric sensitization, and growing preference for long-term preventive treatment. Improved diagnostic availability in primary care and rising collaboration between public hospitals and specialist allergy centers are also supporting SLIT adoption.

Europe Sublingual Allergy Immunotherapy Market Trends and Insights

Europe remains a key SLIT hub due to early adoption of allergen immunotherapy, strong regulatory frameworks, and well-established allergy treatment guidelines. The market is expected to reach ~US$ 460 Mn by 2026, supported by high disease burden and structured reimbursement systems. Europe also benefits from strong clinical acceptance of SLIT tablets and widespread physician familiarity with immunotherapy protocols.

Germany Sublingual Allergy Immunotherapy Market Trends and Insights

Germany leads due to high allergy prevalence affecting nearly 25–30% of the population (EAACI-supported estimates). Strong allergist density, early diagnostic practices, and high patient compliance with long-term therapy significantly support demand. Additional drivers include well-developed insurance reimbursement systems, strong presence of allergy-focused pharmaceutical companies, and high adoption of SLIT in both adult and pediatric populations. Environmental pollution, pollen intensity, and strong preventive healthcare culture further contribute to market expansion.

France Sublingual Allergy Immunotherapy Market Trends and Insights

France is likely to reach positive growth due to increasing pediatric allergy cases and rising awareness of immunotherapy as a long-term solution. Expansion of ENT and allergy clinics, increasing urban pollution exposure, and higher pollen sensitization rates are key drivers. Additional growth factors include improved access to allergy diagnostics, growing physician preference for SLIT over injections, and increasing patient demand for convenient home-based therapies.

Asia Pacific Sublingual Allergy Immunotherapy Market Trends and Insights

Asia-Pacific is the fast-growing market due to rising allergy prevalence, rapid urbanization, and increasing environmental pollution exposure. The market is expected to reach ~US$ 200 Mn in 2026, driven by improving healthcare infrastructure, expanding ENT specialist networks, and increasing awareness of immunotherapy as a long-term disease-modifying approach.

China Sublingual Allergy Immunotherapy Market Trends and Insights

China leads due to rapidly increasing allergic rhinitis prevalence affecting over 100 million people (national epidemiology studies). Strong urban pollution levels, industrial exposure, and lifestyle changes are major contributors. Additional growth drivers include expansion of tertiary hospital allergy departments, increasing government focus on respiratory disease management, rising clinical adoption of immunotherapy, and growing domestic research in allergen vaccines and SLIT formulations.

India Sublingual Allergy Immunotherapy Market Trends and Insights

India is growing rapidly due to rising urban pollution, increasing pollen exposure, and growing awareness of chronic allergy management. Expanding ENT and allergy specialist base in metro cities, improving diagnostic testing availability, and increasing middle-class affordability are key drivers. Additional factors include rising pediatric allergy diagnoses, growing use of private healthcare for advanced treatment, and increasing awareness campaigns by hospitals and specialty clinics promoting immunotherapy adoption.

The global sublingual allergy immunotherapy market is moderately consolidated, with ALK-Abelló, Stallergenes Greer, and Allergopharma (a Merck KGaA subsidiary) commanding the dominant share of standardized SLIT tablet revenues globally. ALK-Abelló’s commercial partnership with Merck for U.S. SLIT tablet distribution provides unmatched North American market reach. Key differentiators include broad allergen coverage, multi-jurisdictional regulatory approvals, reimbursement access, and physician education programs. Emerging competitive strategies encompass multi-allergen SLIT tablet development targeting poly-sensitized patients, pediatric dosing formulations, and digital adherence support platforms. HAL Allergy and Leti Pharma compete effectively through comprehensive allergen extract portfolios across European specialty allergy markets, while Shionogi and regional Asian manufacturers are expanding SLIT footprints in high-growth Asia-Pacific markets.

Key Developments:

• April 2026: ALK Abelló announced positive results from a Phase 2 clinical trial evaluating its tablet-based immunotherapy for peanut allergy. The study demonstrated an early onset of efficacy, with patients showing measurable desensitization to peanut allergens within a shorter treatment period than typically observed in allergen immunotherapy studies.
• April 2025: ITULAZAX® tree pollen tablet was approved in Europe for the treatment of children suffering from tree pollen-induced allergic rhinitis. The approval expanded the indication of the sublingual allergy immunotherapy tablet to a younger pediatric population, addressing a significant unmet need in seasonal respiratory allergies.